New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent
The Pharma Data
JANUARY 26, 2021
Lilly has received feedback from front-line nurses and doctors administering these infusions regarding the complexity and time requirements for preparation and administration. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development and commercialization.
52 
Let's personalize your content